NASDAQ:ALNA - Allena Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.33
  • Forecasted Upside: 612.47 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.31
▼ -0.08 (-5.76%)
1 month | 3 months | 12 months
Get New Allena Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.33
▲ +612.47% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Allena Pharmaceuticals in the last 3 months. The average price target is $9.33, with a high forecast of $18.00 and a low forecast of $4.00. The average price target represents a 612.47% upside from the last price of $1.31.
Buy
The current consensus among 7 investment analysts is to buy stock in Allena Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/3/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/1/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2020B. RileyBoost Price TargetBuy$4.00 ➝ $5.00High
i
9/10/2020WedbushReiterated RatingBuy$18.00Medium
i
Rating by Liana Moussatos at Wedbush
9/10/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by E. White at HC Wainwright
7/15/2020Roth CapitalReiterated RatingBuy ➝ Market Perform$11.00High
i
7/15/2020LADENBURG THALM/SH SHReiterated RatingBuy$8.00High
i
6/2/2020WedbushReiterated RatingBuy$26.00High
i
Rating by Liana Moussatos at Wedbush
6/1/2020HC WainwrightInitiated CoverageBuy$10.00High
i
Rating by E. White at HC Wainwright
3/23/2020WedbushReiterated RatingBuy$26.00Low
i
Rating by Liana Moussatos at Wedbush
3/18/2020Roth CapitalLower Price Target$31.00 ➝ $11.00High
i
3/13/2020B. RileyLower Price TargetBuy$11.00 ➝ $7.00High
i
Rating by Mayank Mamtani at B. Riley
2/17/2020Credit Suisse GroupReiterated RatingHold$4.00High
i
Rating by Martin Auster at Credit Suisse Group AG
2/12/2020B. RileyReiterated RatingBuy$11.00High
i
Rating by Mayank Mamtani at B. Riley
2/12/2020WedbushReiterated RatingBuy$26.00High
i
Rating by Liana Moussatos at Wedbush
1/27/2020WedbushReiterated RatingBuy$26.00High
i
12/5/2019WedbushReiterated RatingBuy$26.00Medium
i
Rating by Liana Moussatos at Wedbush
11/14/2019CowenReiterated RatingBuyLow
i
11/8/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$7.00 ➝ $4.00High
i
Rating by Martin Auster at Credit Suisse Group AG
10/17/2019WedbushReiterated RatingBuy$26.00High
i
Rating by Liana Moussatos at Wedbush
9/6/2019Credit Suisse GroupLower Price TargetPositive ➝ Outperform$26.00 ➝ $7.00Low
i
8/12/2019WedbushReiterated RatingOutperform$36.00Low
i
Rating by Liana Moussatos at Wedbush
8/9/2019CowenReiterated RatingBuyLow
i
8/8/2019Roth CapitalLower Price Target$61.00 ➝ $31.00Low
i
8/5/2019Credit Suisse GroupReiterated RatingOutperform$26.00Low
i
7/10/2019Credit Suisse GroupReiterated RatingOutperformMedium
i
7/2/2019WedbushReiterated RatingBuy$36.00Low
i
Rating by Liana Moussatos at Wedbush
6/21/2019WedbushSet Price TargetBuy$39.00Low
i
Rating by Liana Moussatos at Wedbush
6/5/2019WedbushSet Price TargetBuy$39.00High
i
Rating by Liana Moussatos at Wedbush
5/10/2019CowenReiterated RatingBuyHigh
i
3/10/2019WedbushReiterated RatingBuy$39.00High
i
Rating by Liana Moussatos at Wedbush
3/8/2019B. RileySet Price TargetBuy$22.00High
i
Rating by Mayank Mamtani at B. Riley
1/18/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$20.00Low
i
12/30/2018B. RileyInitiated CoverageBuy$22.00High
i
Rating by Mayank Mamtani at B. Riley
12/21/2018B. RileyReiterated RatingBuy ➝ Buy$22.00High
i
Rating by M. Mamtani at B. Riley
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$22.00High
i
10/23/2018WedbushReiterated RatingBuy$38.00Medium
i
Rating by Liana Moussatos at Wedbush
8/8/2018CowenReiterated RatingBuyHigh
i
8/8/2018B. RileyBoost Price TargetBuy ➝ Buy$23.50 ➝ $25.00High
i
Rating by M. Kumar at B. Riley
8/2/2018LADENBURG THALM/SH SHInitiated CoverageBuy$23.00High
i
7/24/2018WedbushReiterated RatingOutperform$38.00Medium
i
4/25/2018B. RileyInitiated CoverageBuy ➝ Buy$23.50High
i
Rating by M. Kumar at B. Riley
4/2/2018Roth CapitalInitiated CoverageBuy ➝ Buy$61.00High
i
Rating by Y. Rahimi at Roth Capital
3/28/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$22.00 ➝ $21.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
3/28/2018WedbushReiterated RatingOutperform$37.00High
i
Rating by L. Moussatos at Wedbush
3/9/2018WedbushReiterated RatingBuyLow
i
Rating by L. Moussatos at Wedbush
12/18/2017WedbushReiterated RatingBuyMedium
i
Rating by L. Moussatos at Wedbush
11/27/2017WedbushInitiated CoverageOutperform$30.00High
i
Rating by L. Moussatos at Wedbush
11/27/2017CowenInitiated CoverageOutperformHigh
i
11/27/2017Jefferies Financial GroupInitiated CoverageBuy$22.00High
i
11/27/2017Credit Suisse GroupInitiated CoverageOutperform$22.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
(Data available from 10/27/2015 forward)
Allena Pharmaceuticals logo
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Read More

Today's Range

Now: $1.31
$1.30
$1.39

50 Day Range

MA: $1.38
$1.10
$1.69

52 Week Range

Now: $1.31
$0.53
$6.30

Volume

392,817 shs

Average Volume

2,405,680 shs

Market Capitalization

$49.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.54